AGC Biologics, a Bothell, Washington-headquartered contract development and manufacturing organization of biologics, plans to add a new building complex that will house the company’s global headquarters in Bothell.

The new complex is located adjacent to the company’s existing facility in Bothell and spans more than 150,000 square feet (more than 14,000 square meters). The complex will hold the company’s process development laboratories and corporate administrative offices and provide expansion space for additional manufacturing capacity. The new facilities will also include a new research and development center dedicated to manufacturing technologies.

In January 8, 2018, AGC Biologics was formed as new entity from three organizations:  Asahi Glass Company Bioscience, part of Asahi Glass Company, a Tokyo-headquartered glass and chemical producer; Biomeva GmbH, a Heidelberg, Germany-based contract manufacturing organization; and CMC Biologics, a Bothell, Washington-based contract biologics manufacturer.

In March 2018, AGC Biologics announced it is adding a 2,000-liter single-use bioreactor (SUB) to its Berkeley, California facility.

AGC’s Berkeley facility offers cell-culture manufacturing in scales from 100 liters to 3,000 liters, with both single-use bioreactors and stainless-steel bioreactors. In addition to cGMP manufacturing, the facility provides cell-bank manufacturing and storage.

The AGC Biologics Berkeley facility is dedicated to early-phase projects. The team is equipped to cover all early-phase project needs, from cell-line development through manufacturing.

Source: AGC Biologics